peoplePerson
Jie Wang
Led the RATIONALE trials of tislelizumab in lung cancer and many other Chinese registrational NSCLC studies.
Jie Wang has been principal investigator on tislelizumab (RATIONALE-304/307), EGFR-TKI, and ALK trials in NSCLC and on studies of Chinese PD-1 antibodies in small-cell lung cancer.
Role
Professor of Medical Oncology; Cancer Hospital, Chinese Academy of Medical Sciences
Specialisms
Lung cancerImmunotherapyTargeted therapyClinical trials